Please enter the email address you used to register, then we will send you a link to choose a new password
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...
- Preclinical data for VCN-12, the next candidate from Theriva's VCN-X discovery program, highlight a novel mechanism of ac...
U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major benchmark indices were higher.
US stock futures up, Actelis Networks, XCel Brands, Rumble Inc. up after hours. Theriva Biologics to cut workforce, Open Text t...
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics...
https://patentcenter.uspto.gov/applications/18744950/ifw/docs
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1...
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...